Addictive disorders represent a rappidly growing health burden on society. In the US it is estimated that the
abuse of tobacco, alcohol, and illicit drugs is costly to our Nation, exacting more than $740 billion annually in costs related to crime, lost work productivity and health care.
Traditional therapies to treat addictive disorders are burdened with poor compliance, lack of efficacy and/or side effects. OXonium Therapeutics is pioneering the development of a novel class of anti-addictive therapies based on antagonism of the orexin 1 (Ox1) receptor.
Ox1 Antagonism - an exciting new era in anti-addictive therapies
OXonium Therapeutics is developing the best in class Ox1 antagonist with an initial focus on Binge Eating Disorder (BED)
Copyright @ All Rights Reserved